Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Post-transplant cyclophosphamide versus standard GvHD prophylaxis after alloSCT for AML & MDS

Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discusses a study which evaluated risk of relapse and survival outcomes of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving post-transplant cyclophosphamide versus standard graft-versus-host disease (GvHD) prophylaxis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Medexus Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CareDX Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees.